Cost-Effectiveness Analysis of Pharmacogenomics (PGx)-Based Warfarin, Apixaban, and Rivaroxaban Versus Standard Warfarin for the Management of Atrial Fibrillation in Ontario, Canada
ConclusionWe found that PGx-based warfarin for patients with AF is cost-effective at a WTP threshold of C$50,000/QALY. Apixaban had a higher probability of being cost-effective (> 50%) at a WTP threshold of C$93,000/QALY.
Source: PharmacoEconomics - Category: Health Management Source Type: research
More News: Atrial Fibrillation | Canada Health | Coumadin | Databases & Libraries | Genetics | Health Management | Warfarin